Clearmind Medici SEC Filings

Clearmind Medicine Inc. filed a Form 6-K to furnish a press release responding to President Donald J. Trump’s Executive Order titled “Accelerating Medical Treatments for Serious Mental Illness,” which asks the FDA to prioritize review of certain psychedelic drugs designated as breakthrough therapies and to expand patient access pathways.

The company highlights that its proprietary compound MEAI (CMND-100) was previously named in bipartisan bill H.R. 7091 related to veterans’ access to emerging treatments, and that it is running FDA-approved Phase I/IIa clinical trials for CMND-100 in alcohol use disorder at Yale School of Medicine and Johns Hopkins University. Clearmind notes an intellectual property portfolio of nineteen patent families, including 31 granted patents, and states that the first paragraph of the press release is incorporated by reference into several existing Form F-3 and Form S-8 registration statements.

Clearmind Medicine, a clinical-stage biotech, reported a positive safety review from its independent Data and Safety Monitoring Board for its ongoing FDA-approved Phase I/IIa trial of CMND-100 in Alcohol Use Disorder.

The DSMB recommendation followed completion of the third patient cohort and was based on top-line safety data showing CMND-100 was well tolerated with no serious adverse events. This supports a favorable safety and tolerability profile seen in earlier cohorts.

The company will now advance to the fourth cohort and increase the CMND-100 dose to 160mg. The multinational, multicenter study evaluates safety, tolerability, pharmacokinetics and preliminary efficacy of this non-hallucinogenic, MEAI-based oral drug candidate in patients with moderate to severe Alcohol Use Disorder.

Clearmind Medicine Inc. reports updates to its convertible note financing with existing investors. The company agreed to issue and sell new convertible promissory notes with an aggregate principal of $1,750,000, for cash proceeds equal to 90% of principal, or $1,575,000.

The investors then converted $875,000 of these promissory notes into common shares at a fixed conversion price of $0.60 per share. Clearmind and the investors also amended the floor price in the promissory note form attached to the original securities purchase agreements to $0.60 per common share, setting a defined minimum conversion reference level.

Clearmind Medicine Inc. issued and sold convertible promissory notes with an aggregate principal amount of $1,750,000 to existing CLA investors under previously signed securities purchase agreements. The notes were sold for a cash purchase price equal to 90% of principal, providing $1,575,000 in proceeds on April 14, 2026.

The notes are part of a broader facility allowing issuance of up to $10,000,000 in aggregate principal amount of convertible promissory notes. This report is incorporated by reference into Clearmind’s existing Form F-3 and Form S-8 registration statements.

Clearmind Medicine Inc. reported that its oral drug candidate CMND-100, a non-hallucinogenic MEAI-based therapy for alcohol use disorder, met the primary safety and tolerability endpoint in an FDA-approved Phase I/IIa clinical trial.

Data from the trial’s third cohort showed CMND-100 was well tolerated at the highest dose tested so far, with no serious adverse events and a high safety profile consistent with earlier cohorts. The multinational, multicenter study is also assessing pharmacokinetics and preliminary efficacy in patients with moderate to severe alcohol use disorder. The company highlights this milestone as supporting continued development of CMND-100 as a potential novel treatment option.

Clearmind Medicine Inc. reported progress in its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, a proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder. The company has successfully completed treatment and follow-up for 18 participants, marking a key early-stage milestone in assessing safety, tolerability, pharmacokinetics, and preliminary efficacy.

Clearmind also completed treatment for four additional participants at its Tel Aviv clinical center, highlighting expanding enrollment and operational strength at its Israeli sites. The trial is being run at leading institutions including Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Clearmind describes itself as a clinical-stage neuroplastogens pharmaceutical biotech with nineteen patent families and 31 granted patents focused on non-hallucinogenic, second-generation therapeutics for underserved conditions such as Alcohol Use Disorder.

Clearmind Medicine Inc., a clinical-stage biotech company focused on non-hallucinogenic, second-generation neuroplastogen-derived therapeutics, has filed a patent application in India for innovative psychedelic-based compounds aimed at treating mental health disorders and addiction. The application, submitted to the Indian Patent Office, extends the company’s global intellectual property portfolio and builds on its exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.

The patent seeks to protect novel compounds designed to address limitations of classical psychedelics, with the goal of providing potentially safer, more effective and scalable treatments for underserved mental health and addictive conditions. Clearmind reports that its intellectual property portfolio currently includes nineteen patent families and 31 granted patents, and it plans to continue pursuing additional patents and related IP opportunities.

Clearmind Medicine Inc. files a post-effective amendment registering the resale of up to 331,949 common shares issuable upon exercise of January 2024 PIPE Warrants. The prospectus combines previously effective registration statements and covers shares issuable from time to time upon warrant exercise.

The selling shareholders will receive net proceeds from any resale; the company will not receive proceeds unless warrants are exercised for cash. The filing notes 2,394,806 common shares outstanding as of March 24, 2026 and states the registered shares equal approximately 15.89% of outstanding shares prior to the offering.